Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Cancer Institute Directors Consumer Liaison Group.
The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.
Name of Committee: National Cancer Institute Director's Consumer Liaison Group.
Date: May 26, 2005.
Time: 3 p.m. to 5 p.m.
Agenda: Opening remarks; approval of minutes February 28-March 1, 2005 DCLG meeting; NCI Director's Remarks; reports from NCI Listens and Learns Working Groups: Operations Working Group, Summit Working Group, Promotions Working Group, and Evaluation Working Group; DCLG recommendations on the Progress Review Group Process; public comment; next steps.
Place: National Institutes of Health, 6116 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call).
Contact Person: Nancy Caliman, Executive Secretary, Office of Liaison Activities, National Institutes of Health, National Cancer Institutes, 6116 Executive Boulevard, Suite 220, MS8324, Bethesda, MD 20892, (301) 496-0307, firstname.lastname@example.org.
Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.
Information is also available on the Institute's/Center's home page: http://deainfo.nci.nih.gov/advisory/dclg/dclg.htm, where an agenda and any additional information for the meeting will be posted when available.Start Signature
(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS.)
Dated: April 25, 2005.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 05-8779 Filed 5-2-05; 8:45 am]
BILLING CODE 4140-01-M